title: Radiosensitization effect of nedaplatin on nasopharyngeal carcinoma cells in different status of Epstein-Barr virus infection.
abstract: This study aims to evaluate the radiosensitization effect of nedaplatin on nasopharyngeal carcinoma (NPC) cell lines with different Epstein-Barr virus (EBV) status. Human NPC cell lines CNE-2 (EBV-negative) and C666 (EBV-positive) were treated with 0-100 μg/mL nedaplatin, and inhibitory effects on cell viability and IC50 were calculated by MTS assay. We assessed changes in radiosensitivity of cells by MTS and colony formation assays, and detected the apoptosis index and changes in cell cycle by flow cytometry. MTS assay showed that nedaplatin caused significant cytotoxicity in CNE-2 and C666 cells in a time- and dose-dependent manner. After 24 h, nedaplatin inhibited growth of CNE-2 and C666 cells with IC50 values of 34.32 and 63.69 μg/mL, respectively. Compared with radiation alone, nedaplatin enhanced the radiation effect on both cell lines. Nedaplatin markedly increased apoptosis and cell cycle arrest in G2/M phase. Nedaplatin radiosensitized human NPC cells CNE-2 and C666, with a significantly greater effect on the former. The mechanisms of radiosensitization include induction of apoptosis and enhancement of cell cycle arrest in G2/M phase.
authors.affiliation: Jiangsu Cancer Hospital, Nanjing Medical University, Nanjing 210009, China ; Jiangsu Key Laboratory of Molecular and Translational Cancer Research, Nanjing 210009, China.
authors.forename: Li
authors.identifier: 0000-0001-5280-0075
authors.initials: L
authors.lastname: Yin
authors.affiliation: Jiangsu Cancer Hospital, Nanjing Medical University, Nanjing 210009, China ; Jiangsu Key Laboratory of Molecular and Translational Cancer Research, Nanjing 210009, China.
authors.forename: Jing
authors.initials: J
authors.lastname: Wu
authors.affiliation: Jiangsu Cancer Hospital, Nanjing Medical University, Nanjing 210009, China.
authors.forename: Jianfeng
authors.initials: J
authors.lastname: Wu
authors.affiliation: Jiangsu Cancer Hospital, Nanjing Medical University, Nanjing 210009, China.
authors.forename: Jinjun
authors.initials: J
authors.lastname: Ye
authors.affiliation: Jiangsu Cancer Hospital, Nanjing Medical University, Nanjing 210009, China.
authors.forename: Xuesong
authors.initials: X
authors.lastname: Jiang
authors.affiliation: Jiangsu Cancer Hospital, Nanjing Medical University, Nanjing 210009, China ; Jiangsu Key Laboratory of Molecular and Translational Cancer Research, Nanjing 210009, China.
authors.forename: Meng
authors.initials: M
authors.lastname: Chen
authors.affiliation: Jiangsu Cancer Hospital, Nanjing Medical University, Nanjing 210009, China.
authors.forename: Dejun
authors.initials: D
authors.lastname: Wang
authors.affiliation: Jilin Cancer Hospital, Changchun 130012, China.
authors.forename: Xue
authors.initials: X
authors.lastname: Wang
authors.affiliation: Jiangsu Cancer Hospital, Nanjing Medical University, Nanjing 210009, China ; Jiangsu Key Laboratory of Molecular and Translational Cancer Research, Nanjing 210009, China.
authors.forename: Dan
authors.initials: D
authors.lastname: Zong
authors.affiliation: Jiangsu Cancer Hospital, Nanjing Medical University, Nanjing 210009, China ; Jiangsu Key Laboratory of Molecular and Translational Cancer Research, Nanjing 210009, China.
authors.forename: Jiajia
authors.initials: J
authors.lastname: Gu
authors.affiliation: Department of Oncology, Xuzhou Medical College, Xuzhou 221004, China.
authors.forename: Junying
authors.initials: J
authors.lastname: Zhang
authors.affiliation: Jiangsu Key Laboratory of Molecular and Translational Cancer Research, Nanjing 210009, China.
authors.forename: Jianzhong
authors.initials: J
authors.lastname: Wu
authors.affiliation: Jiangsu Cancer Hospital, Nanjing Medical University, Nanjing 210009, China ; Jiangsu Key Laboratory of Molecular and Translational Cancer Research, Nanjing 210009, China.
authors.forename: Lin
authors.initials: L
authors.lastname: Xu
authors.affiliation: Jiangsu Cancer Hospital, Nanjing Medical University, Nanjing 210009, China ; Jiangsu Key Laboratory of Molecular and Translational Cancer Research, Nanjing 210009, China.
authors.forename: Xia
authors.identifier: 0000-0003-1247-9103
authors.initials: X
authors.lastname: He
authors.affiliation: Jiangsu Cancer Hospital, Nanjing Medical University, Nanjing 210009, China.
authors.forename: Wenjie
authors.initials: W
authors.lastname: Guo
mesh_terms: D017209:Apoptosis / Q000187:drug effects; D002277:Carcinoma; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D020031:Epstein-Barr Virus Infections / Q000821:virology*; D059565:G2 Phase Cell Cycle Checkpoints / Q000187:drug effects; D004854:Herpesvirus 4, Human; D006801:Humans; D000077274:Nasopharyngeal Carcinoma; D009303:Nasopharyngeal Neoplasms / Q000188:drug therapy* / Q000821:virology*; D009944:Organoplatinum Compounds / Q000494:pharmacology*; D011836:Radiation Tolerance; D011838:Radiation-Sensitizing Agents / Q000494:pharmacology*
chemical_list: D009944:Organoplatinum Compounds; D011838:Radiation-Sensitizing Agents; C053989:nedaplatin